stockrow
Friday 6 November 2026
Export EQ’s income statement to Excel — free account
Equillium, Inc.
Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023.
- Revenue
- −52.3%
- EPS
- +75.0%
- Free cash flow
- −38.7%
Quarter to June 2026, against a year earlier
1.34
0.06
−4.29%
Follow EQ
Alert me
Equillium, Inc. (EQ) P/E ratio
Equillium, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GNLX Genelux Corporation compare | n/m |
| NRXS Neuraxis, Inc. compare | n/m |
| EQ Equillium, Inc. | n/m |
| CLLS Cellectis S.A. compare | n/m |
| PLYX Polaryx Therapeutics, Inc. compare | n/m |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | n/m |
| KZIA Novogen Limited compare | n/m |
| VXRT VAXART, INC. compare | 2.8× |
| RLYB Rallybio Corporation compare | 3.3× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)